By the end of this video, you will be able
to list the common animal species that are encountered in preclinical studies. You will also be able
to explain how specific species are chosen for
a particular drug program. The general toxicology studies perform
toward the end of the drug discovery phase generate vital safety information
for the IND application, or CTA. These safety studies are generally
expected to include one rodent and one non-rodent species. Regulatory guidelines do not
require any specific species, but only a few species are commonly
encountered, mouse or rat for rodents and dog or
non-human primate for non-rodents. Non-human primates are monkeys,
typically macaques, while other species could possibly be
used, the amount of historical data on these few species provides a strong
baseline for determining safety risks. For small molecule drug projects, rats
are the most common rodent species and dogs are the most common
non-rodent species. The species used in safety studies
can vary based on how the molecule behaves in each species. Properties such as drug metabolism,
pharmacokinetic properties, and tendencies for a species to show
adverse effects will be considered. A species that shows a somewhat
similar metabolic profile to humans may be favored in a toxicology study. One practical consideration is whether
a particular animal species expresses a homolog of the human target at which the
drug candidate is expected to be active. If not, that species would not
be ideal for safety studies, as this would not test for
on target toxicity. This same idea is important when
investigating biological drugs such as monoclonal antibodies and
protein therapeutics. Antibody toxicology studies are often
limited to monkeys in which an antibody against a human target is most likely to
have cross reactivity to a monkey target. If this crossreactivity does not exist, the drug hunting team may need to create
another version of the antibody with the required crossreactivity in order
to investigate on target toxicity. Similarly, studies of protein
therapeutics can generate non informative immunologic
responses in animal species. Using nonhuman primates,
which are most similar to humans, can minimize the incidence of
misleading immunologic responses. The treatment and care of animals used
in safety studies is highly regulated. In the United States, procedures
are covered under the Animal Welfare Act. Regulations provide requirements for
humane treatment, transport, and housing of the animals. In order to minimize the need for
using animals in toxicology studies, pharmaceutical companies follow the 3R's
replacement, reduction, and refinement. Replacement includes the use of in
vitro technologies such as cell or tissue culture as early drug screens
prior to the conduct of animal studies, the use of computational predictions or cell based organ on a chip
methods in place of live animals. Reduction advocates for
the use of fewer animals or maximizing the amount of information
gained per animal studied. Refinement minimizes stress on the animals
through methods such as digital technologies to observe animals
in their home environments, and minimally invasive telemetry,
along with animal husbandry practices such as socialization and
enrichment procedures. Concerning this last point of animal
welfare, research programs are highly motivated to provide the best possible
living conditions for animals. Distressed animals tend to have poorer
health outcomes that lead to spurious data having little or no relevance
to the chemical entity being tested. Preclinical toxicology studies
performed before an IND application or CTA require results from both a rodent and
non-rodent species. The results of these studies help
determine safety expectations for a molecule once it enters the clinic.